Week 225 Review - Promising start ends up deepening loss

The week started off quite well and was £2,000 up by Wednesday, but it didn't last and a 2p drop in OPTI:Optibiotix was enough to drag the whole portfolio down by £2,011. The deficit between cost and value widened to £32,584 and the portfolio value dropped to £72,572.

Worst performer was SBTX:SkinBioTherapeutics which dropped 13% despite last week's great news. I think people were expecting figures to show instant profits, and the potential 2 year wait for product development has caused a big sell-off. There's one thing for sure - if it stays at 16p until my pension transfer arrives next week, I'll be putting the whole lot in here and throwing away my "dividend-paying shares only" rule before I even managed to start it.

IQE:IQE recovered 7% of its value after last week's big crash. I'm still massively under water in all my accounts and suspect I will be until 5g starts rolling out, when maybe these will start making some profit.

Share of the Week is IKA:Ilika which climbed 13%, but it's done that before and sunk again when it became clear there isn't anyone in the company with a remotely commercial brain. There's just a glimmer of hope that their joint venture with Toyota may bear some fruit, which seems to be what sparked off this rise.

That orange line has a magnetic quality about it.

Almost exactly following the trend line - downwards!

Here's the ISA and share accounts

			Weekly Change
Cash	£19.49		+£0
Portfolio cost	£57,768.95		+£0
Portfolio sell value (bid price-commission)	£38,369.08	(-33.6%)	-£1,059.98
Potential profits	£0		+£0
Yr 5 Dividends	£0.63		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£45.35	(-0.9%)	+£2.83
Total Dividends	£1,342.93		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£411.46	(8.5%)	-£1.84
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	13.2%		-0.1%
Compound performance	57%		+0%

Another drop of over £1,000 and still no shares in the black. A grim picture.

Almost back to the dreaded injection line.

Back touching the (downward pointing) trend line.

The SIPP looks like this after week 209 as we start year 5 and re-set the annual figures to zero.

			Weekly Change
Cash	£103.32		+£0.04
Portfolio cost	£44,895.31		+£0
Portfolio sell value (bid price - commission)	£32,822.71	(-26.9%)	-£952.99
Potential profits	£392.97		+£0
Yr 5 Dividends	£0		+£0
Yr 5 Interest	£0		+£0
Yr 5 Profit from sales	£0		+£0
Yr 5 Average monthly cash profit	£0	(0%)	+£0
Total Dividends	£1,899.24		+£0
Total Interest	£0.17		+£0.04
Total Profit from sales	£12,549.10		+£0
Average monthly cash profit	£290.38	(7.8%)	-£1.39
(Sold stocks profit + Dividends - Fees / Months)
Performance/Injection	12.5%		-0.1%
Compound performance	50%		+0%

I hadn't noticed 4p interest that arrived a few weeks ago which is why the cash and overall interest are up. It should have been included in the year 4 figures so I've left year 5 as £0. The drop was slightly less than £1,000 which is a small saving grace.

As usual this account is a little better behaved than the ISA

It may be better behaved, but it's further below the trend line.

The trading account looks like this

			Weekly Change
Cash	£48.24		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,209.48	(-47.9%)	+£1.97
Potential profits	£0		+£0
Year 4 Dividends	£13.20		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£3.01	(1.6%)	-£0.17
Dividends	£47.92		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.41	(-0.2%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	-0.2%		+0%
Compound performance	-1%		+0%

This account is up on the week - albeit by less than £2. No real change in the figures and still no chance of selling anything.

Well below the trend line and in very poor shape.

I should get my pension transfer by the end of the week. My plans to put half in D4T4:D4T4 Solutions has been scrapped after their interim results that had some red flags. They are doing what MAIS:Maistro did and transitioning to a SaaS model, which is fair enough, but they are claiming this is a reasonable explanation for dropping H1 income by 40%. I'm all for having an H2 weighted income stream as long as H1 compares favourably with last year's H1, but a 40% drop rang enough alarm bells for me to keep watching from the sidelines.

CAML:Central Asia Metals are still low enough for me to consider buying them, and meet my new dividend paying rule. However with SBTX:SkinBioTherapeutics dropping to my buy target of 16p I will get those if the money comes through in time and suspend my new rule. It's more of a guideline really...